Intuitive Surgical (ISRG)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-29
$448.76+1.03%
Close 2026-10-29 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-29
Research Workspace
Put ISRG beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 20% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 15%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins.
View ManagementExpectations look high — the market is pricing in about 24% growth a year, above the roughly 13% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskIntuitive Surgical’s da Vinci procedure volume growth has to sustain its premium valuation. Revenue growth slowed from 23% to 22% year over year, though Q3 beat. That quarter’s non-GAAP EPS beat by 40.8%. ISRG trades at 43× P/E versus a 30× peer median, near its 44× history. The market prices more growth than our forecast, making the peer premium vulnerable. Our model puts the next-quarter miss probability near 14%. Peer multiples imply a price about 24% below where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-29. ISRG is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 36 analysts currently covering ISRG (as of Oct 2026).
Based on 16 Wall Street analysts offering 12-month price targets for ISRG in the last 4 months.
Continue this research
Compare ISRG with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ISRG Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put ISRG next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Increase da Vinci procedure volume
Official earnings-call transcript may clarify procedure growth and operating objectives, but headline gives no results.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $448.76
The last 12 months of price, then the range of analyst 12-month targets from today’s $448.76.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Maintain non-GAAP gross profit margin
Reported pretax charge drove a sharp earnings reaction and pressures margin expectations.
Threatens: Increase da Vinci procedure volume
Sell case highlights potential risks to growth.
Threatens: Increase da Vinci procedure volume
Procedure growth persists, but U.S. slowdown and China pressure are real demand headwinds.
New competitor could impact da Vinci procedure volume growth.
Expand adoption of da Vinci, Ion, and digital platforms
Official management conference transcript may update platform adoption and growth outlook; headline states no specifics.
Threatens: Increase da Vinci procedure volume
Reported growth slowdown is a headwind, while maintained outlook limits the concern.
Advances: Increase da Vinci procedure volume
AI innovations can significantly enhance da Vinci procedure volume.
